The Hyderabad-based Aurobindo Pharma Ltd today said it has received the tentative new drug approval for a fixed drug combination product used for anti-HIV treatment.
The fixed drug compbination product contains Lamivudine 150mg+2idovudine300mg tablets co-packaged with Abacavir 300mg Tablets, the company informed the Bombay Stock Exchange.
This combination pack enhances convenience, is cost-effective and reduces the threat of resistance due to missed doses.
This is the first new drug generic approval in the world for a three-drug combination pack. These three drugs command over six hundred million-dollar market worldwide and the usage of the drugs is growing.
With this approval, the antiretroviral product portfolio of Aurobindo increased to 18 including three NDA approvals.
The shares of the company were trading at Rs 640.05, up 2.52 per cent at the BSE.